F Haroun, MD

👨‍🏫 Hematology & Oncology University of Minnesota (previously at GWU). Thoracic and Head&Neck cancer.

[F Haroun, MD @Cancer_talks]

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Wisconsin https://t.co/i4BDMPi5AS

[F Haroun, MD @Cancer_talks]

#APPOS APP oncology summit. Discussing NSCLC #lcsm #fairview #umncancer

[F Haroun, MD @Cancer_talks]

@appos APP oncology summit in Minneapolis!
Discussing NSCLC #lcsm #UMNCancer

[GW Cancer Center @GWCancer]

Sonal Paul, MD, Joins the George Washington University Cancer Center as a Hematologist-Oncologist

Welcome to GW Cancer Center, Dr. Paul!

https://t.co/o10Xeybger

[F Haroun, MD @Cancer_talks]

Immensely proud of our GW #hemonc fellows. Humbled by their maturity and professionalism, and confident that they will provide patients with the most compassionate and informed care.
#graduation @GW_MFA @GWCancer @GWSMHS
This group would make any PD proud!

[F Haroun, MD @Cancer_talks]

Durvalumab consolidation for pts with limited-stage small-cell lung ca Spigel #lcsm #asco24

The poor prognosis of SCLC even in limited stg disease translated to an OS benefit in the #ADRIATIC mirroring the CASPIAN results. Different SEA similar wave with 10% absolute OS benefit

[F Haroun, MD @Cancer_talks]

Osimertinib after def CRT in pts with unresectable stg III EGFRm NSCLC
phase 3 LAURA stud: Suresh Ramalingam
Impressive PFS benefit with Osi is not a surprise. High recurrence rates drive the benefit- delay in recurrence is a clinically sign, PFS ≠ OS ≠ cure #Lcsm #asco24

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO

➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️
➡️ 24-mo PFS: 65% vs 13% 📈
➡️ 81% received osi at progression 💊, Good!
➡️AE discontinuation**: 13% vs 5% ⚠️

Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert

[F Haroun, MD @Cancer_talks]

Neoadjuvant nivo plus ipi
versus adj nivo in macro, resectable st Ill #melanoma: The phase
3 #NADINA trial #asco24 Dr.Blank
Impressive PFS benefit of 2 cycles of neoadjuvant vs a standard of care adj approach.
Benefit shorter duration of therapy
Negative more iAE with CTLA4

[F Haroun, MD @Cancer_talks]

Results
#asco24 #lcsm

[F Haroun, MD @Cancer_talks]

Amivantamab plus lazertinib vs osimertinib
in 1st line EGFR-mu advanced NSCLC with high-risk disease
2ndary analysis of phase 3
MARIPOSA Dr.Enriqueta Felip

PFS HR 0.7
High risk: brain met (41%), Liver met at baseline (16%), Detectable baseline cDNA by NGS° (85%) TP53 co-mu (54%)

[F Haroun, MD @Cancer_talks]

CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC - 5-Year Follow-Up

At 5yrs PFS: Lorlatinib 60% (5-yr) vs Crizotinib 8%
Lorlatinib IC DFS >93% with HR0.03

Grade 3/4 AEs: 77% Lorlatinib vs 57% Crizotinib #asco24 #lcsm

[F Haroun, MD @Cancer_talks]

Sacituzumab tirumotecan (SKB264/
MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase Il OptiTROP-Lung01 study.
Wenfeng Fang, MD, PhD

[F Haroun, MD @Cancer_talks]

ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in
pts with previously treated NSCLC with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.
#DavidPlanchard
#asco24 #lcsm

[F Haroun, MD @Cancer_talks]

Sacituzumab govitecan (SG) vs docetaxel
in pts with mNSCLC
previously treated with platinum chemo and PD(L)-inhibitors
Primary results from the phase 3 EVOKE-01 study
OS- no benefit- subgroup may show benefit in patient without a prior response to PD inhibition.
#asco24 #lcsm

[F Haroun, MD @Cancer_talks]

Back in Chicago for ASCO, excited to see that breakthroughs in lung cancer are dominating the meeting.

#asco #asco2024 #lcsm

[Charbel Matar @Charbel_matar1]

Thrilled to be part of this amazing talented group of featured voices #ASCO2024 for the third year 🎉 Follow the team for more insight on the most updated conference in Oncology 2024.

@HamidMD10 @jacobadashek @TwoOncDocs @DarcyBurbage @fumikochino @DevikaDasMD @ADesaiMD

[F Haroun, MD @Cancer_talks]

I welcome the +ve #LAURAIII trial for #Osimertinib post ChemoRT in locally advanced EGFRm NSCLC despite the indefinite indication/design

Cure in stage III NSCLC continues to be the aim but isn’t the norm
Longterm DFS (🫣OS trend) is a huge step forward.

https://t.co/LICmPmJU6Q